Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.
Volatility & Risk
Lyell Immunopharma has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500.
Institutional and Insider Ownership
66.1% of Lyell Immunopharma shares are owned by institutional investors. 22.3% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -794,292.69% | -96.68% | -76.00% |
| Telomir Pharmaceuticals | N/A | -566.61% | -447.89% |
Valuation & Earnings
This table compares Lyell Immunopharma and Telomir Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $60,000.00 | 8,942.04 | -$342.99 million | ($23.02) | -1.10 |
| Telomir Pharmaceuticals | N/A | N/A | -$16.53 million | ($0.37) | -3.62 |
Telomir Pharmaceuticals has lower revenue, but higher earnings than Lyell Immunopharma. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Lyell Immunopharma and Telomir Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 0 | 1 | 0 | 2.00 |
| Telomir Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
Lyell Immunopharma currently has a consensus price target of $45.00, indicating a potential upside of 78.15%. Telomir Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 1,019.40%. Given Telomir Pharmaceuticals’ higher probable upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Lyell Immunopharma.
Summary
Lyell Immunopharma beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
